RedHill Biopharma Ltd. (RDHL)
USD 2.29
(2.23%)
USD 2.29
(2.23%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 23.91 Million USD | 140.37% |
| 2022 | -59.24 Million USD | 48.17% |
| 2021 | -114.31 Million USD | -28.41% |
| 2020 | -89.01 Million USD | -104.01% |
| 2019 | -43.63 Million USD | -12.4% |
| 2018 | -38.82 Million USD | 14.76% |
| 2017 | -45.54 Million USD | -55.07% |
| 2016 | -29.37 Million USD | -39.26% |
| 2015 | -21.09 Million USD | -96.9% |
| 2014 | -10.71 Million USD | -0.78% |
| 2013 | -10.62 Million USD | -2.92% |
| 2012 | -10.32 Million USD | 33.39% |
| 2011 | -15.5 Million USD | -509.39% |
| 2010 | -2.54 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | 761 Thousand USD | -98.49% |
| 2023 Q1 | 50.24 Million USD | 1917.71% |
| 2023 FY | 23.91 Million USD | 140.37% |
| 2022 Q3 | -64.29 Million USD | -350.77% |
| 2022 Q1 | -17.13 Million USD | 29.69% |
| 2022 Q2 | -14.26 Million USD | 16.77% |
| 2022 FY | -59.24 Million USD | 48.17% |
| 2022 Q4 | 2.49 Million USD | 103.87% |
| 2021 Q2 | -29.12 Million USD | -27.37% |
| 2021 Q3 | -21.38 Million USD | 26.56% |
| 2021 Q4 | -24.37 Million USD | -13.96% |
| 2021 FY | -114.31 Million USD | -28.41% |
| 2021 Q1 | -22.86 Million USD | 6.03% |
| 2020 FY | -89.01 Million USD | -104.01% |
| 2020 Q1 | -17.15 Million USD | -46.75% |
| 2020 Q2 | -16.04 Million USD | 6.47% |
| 2020 Q3 | -18.63 Million USD | -16.15% |
| 2020 Q4 | -24.33 Million USD | -30.55% |
| 2019 Q3 | -9.83 Million USD | 9.84% |
| 2019 Q1 | -9.87 Million USD | -28.45% |
| 2019 Q2 | -10.9 Million USD | -10.52% |
| 2019 FY | -43.63 Million USD | -12.4% |
| 2019 Q4 | -11.69 Million USD | -18.87% |
| 2018 FY | -38.82 Million USD | 14.76% |
| 2018 Q4 | -7.68 Million USD | 23.79% |
| 2018 Q3 | -10.08 Million USD | 9.31% |
| 2018 Q2 | -11.11 Million USD | -11.91% |
| 2018 Q1 | -9.93 Million USD | 4.59% |
| 2017 Q3 | -15.51 Million USD | -40.72% |
| 2017 Q4 | -10.41 Million USD | 32.87% |
| 2017 FY | -45.54 Million USD | -55.07% |
| 2017 Q2 | -11.02 Million USD | -28.23% |
| 2017 Q1 | -8.59 Million USD | -2.96% |
| 2016 FY | -29.37 Million USD | -39.26% |
| 2016 Q4 | -8.34 Million USD | 6.65% |
| 2016 Q3 | -8.94 Million USD | -36.51% |
| 2016 Q2 | -6.55 Million USD | -18.61% |
| 2016 Q1 | -5.52 Million USD | 15.79% |
| 2015 Q1 | -4.64 Million USD | 12.88% |
| 2015 FY | -21.09 Million USD | -96.9% |
| 2015 Q4 | -6.56 Million USD | -99.27% |
| 2015 Q3 | -3.29 Million USD | 50.09% |
| 2015 Q2 | -6.59 Million USD | -42.09% |
| 2014 FY | -10.71 Million USD | -0.78% |
| 2014 Q4 | -5.32 Million USD | -25.78% |
| 2014 Q2 | -4.52 Million USD | -233.97% |
| 2014 Q1 | 3.37 Million USD | 198.17% |
| 2014 Q3 | -4.23 Million USD | 6.37% |
| 2013 FY | -10.62 Million USD | -2.92% |
| 2013 Q2 | -2.51 Million USD | -27.06% |
| 2013 Q1 | -1.97 Million USD | 41.02% |
| 2013 Q3 | -2.69 Million USD | -7.44% |
| 2013 Q4 | -3.44 Million USD | -27.45% |
| 2012 Q4 | -3.35 Million USD | -70.41% |
| 2012 Q1 | -2.73 Million USD | -4.35% |
| 2012 Q3 | -1.96 Million USD | 13.46% |
| 2012 Q2 | -2.27 Million USD | 16.86% |
| 2012 FY | -10.32 Million USD | 33.39% |
| 2011 FY | -15.5 Million USD | -509.39% |
| 2011 Q3 | -2.72 Million USD | 0.0% |
| 2011 Q4 | -2.62 Million USD | 3.99% |
| 2010 FY | -2.54 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 117.123% |
| PainReform Ltd. | -9.34 Million USD | 355.95% |
| Alvotech | -551.73 Million USD | 104.335% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 50.335% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | -27.355% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 403.888% |
| Journey Medical Corporation | -3.85 Million USD | 720.711% |
| Dynavax Technologies Corporation | -6.38 Million USD | 474.331% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 111.429% |
| Bright Green Corporation | -13.12 Million USD | 282.18% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 42.996% |
| Embecta Corp. | 70.4 Million USD | 66.028% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 630.754% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 630.754% |
| SCYNEXIS, Inc. | 67.04 Million USD | 64.326% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 392.974% |
| Silver Spike Investment Corp. | 7.34 Million USD | -225.826% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 871.849% |
| Alpha Teknova, Inc. | -36.78 Million USD | 165.024% |
| Safety Shot Inc | -15.08 Million USD | 258.562% |
| Procaps Group, S.A. | 42.54 Million USD | 43.78% |
| Cosmos Health Inc. | -18.54 Million USD | 228.978% |
| Theratechnologies Inc. | -23.95 Million USD | 199.829% |
| Harrow Health, Inc. | -24.41 Million USD | 197.972% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 594.643% |
| Biofrontera Inc. | -20.13 Million USD | 218.802% |
| DURECT Corporation | -27.62 Million USD | 186.577% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -1717.325% |
| Cronos Group Inc. | -73.96 Million USD | 132.335% |
| OptiNose, Inc. | -35.48 Million USD | 167.401% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 102.386% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 156.674% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -383.64% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -15033.548% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 480.869% |
| Radius Health, Inc. | -25.79 Million USD | 192.73% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 488.054% |
| ProPhase Labs, Inc. | -16.78 Million USD | 242.51% |
| Phibro Animal Health Corporation | 2.41 Million USD | -889.901% |
| Procaps Group S.A. | 42.54 Million USD | 43.78% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 332.691% |
| Viatris Inc. | 54.7 Million USD | 56.278% |
| Rockwell Medical, Inc. | -8.43 Million USD | 383.399% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 250.947% |
| SIGA Technologies, Inc. | 68.06 Million USD | 64.865% |
| Tilray Brands, Inc. | -244.98 Million USD | 109.762% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -99.084% |
| Shineco, Inc. | -22.44 Million USD | 206.535% |
| PetIQ, Inc. | 2.13 Million USD | -1022.29% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 655.949% |
| Incannex Healthcare Limited | -18.45 Million USD | 229.563% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 90.422% |
| Alimera Sciences, Inc. | -20.13 Million USD | 218.796% |
| Assertio Holdings, Inc. | -331.94 Million USD | 107.205% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 462.764% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 233.616% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 219.238% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 114.922% |
| Hempacco Co., Inc. | -13.12 Million USD | 282.202% |
| Talphera, Inc. | -18.39 Million USD | 229.999% |
| Alvotech | -551.73 Million USD | 104.335% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 32.899% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 92.679% |
| Currenc Group, Inc. | -15.3 Million USD | 256.247% |
| Kamada Ltd. | 8.28 Million USD | -188.701% |
| Indivior PLC | 2 Million USD | -1095.8% |
| Evoke Pharma, Inc. | -7.79 Million USD | 406.919% |
| Flora Growth Corp. | -57.03 Million USD | 141.931% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 219.238% |
| Evolus, Inc. | -61.68 Million USD | 138.771% |
| HUTCHMED (China) Limited | 100.78 Million USD | 76.269% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 82.612% |
| Akanda Corp. | -32.27 Million USD | 174.101% |